Previous close | 55.14 |
Open | 55.14 |
Bid | 41.00 |
Ask | 50.60 |
Strike | 280.00 |
Expiry date | 2024-06-21 |
Day's range | 55.14 - 55.14 |
Contract range | N/A |
Volume | |
Open interest | 100 |
Biogen, Eli Lilly's, Prothena and AC Immune are included in this Analyst Blog.
If Eli Lilly's (LLY) donanemab is approved by the FDA, it will become the second drug approved by the FDA to reduce the clinical decline associated with Alzheimer's disease.
An outside panel agreed unanimously that donanemab is an effective treatment and that its benefits outweighed its risks.